SCHEMBL368117

SCHEMBL368117

C1CC2CNCC2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1222699 1.00
SCHEMBL14224211 1.00
SCHEMBL9595589 1.00 CCR5 (0.42)
SCHEMBL3710709 1.00
SCHEMBL4748801 0.85 CCR5 (0.36)
SCHEMBL4814979 0.85 MBTD1 (0.33)
SCHEMBL660910 0.84 CCR5 (0.32)
SCHEMBL64396 0.84
SCHEMBL1724943 0.84
SCHEMBL7496575 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP claimed
EP-4688784-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP claimed
US-12486260-B2 Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer MERCK PATENT GMBH (DE) 2025-12-02 US claimed
EP-4611743-A1 TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-09-10 EP claimed
EP-4543544-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-04-30 EP claimed
CN-119866338-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-22 CN claimed
US-12157094-B2 Gas separation method with multilayer membrane KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-12-03 US claimed
US-12138596-B2 Method for separating carbon dioxide and methane KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-11-12 US claimed
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 US claimed
EP-4448105-A1 HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE VIR Biotechnology, Inc. (US) 2024-10-23 EP claimed
WO-2008128647-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-10-30 WO claimed
WO-2008041090-A1 MALANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONIST PYRIDINONES PFIZER LIMITED (GB) 2008-04-10 WO claimed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US claimed
EP-0350733-B1 7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives, method for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions BAYER AG (DE) 1997-08-20 EP claimed
EP-0393424-B1 Process for the preparation of 2,7-Diazabicyclo(3.3.O)octanes BAYER AG (DE) 1995-09-27 EP claimed
US-5241076-A 1,4-diazatricyclo [6.3.0.0]undecanes BAYER AKTIENGESELLSCHAFT (DE) 1993-08-31 US claimed
US-5177210-A Preparation of 2,7-diazabicyclo(3.3.0)octanes BAYER AKTIENGESELLSCHAFT (DE) 1993-01-05 US claimed
US-5071999-A Preparation of 2,7-diazabicyclo[3.3.0]octanes BAYER AKTIENGESELLSCHAFT (DE) 1991-12-10 US claimed
EP-0393424-A2 Process for the preparation of 2,7-Diazabicyclo(3.3.O)octanes BAYER AG (DE) 1990-10-24 EP claimed
EP-0350733-A2 7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives, method for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions BAYER AG (DE) 1990-01-17 EP claimed